This is a competitive renewal application for the Cancer Center Support Grant of Roswell Park Cancer Institute (RPCI). an NCI-designated Comprehensive Cancer Center, for the grant period 1985 - 2000. Under the leadership of Institute President and CEO, Thomas B. Tomasi, M.D., Ph.D, this grant is entering its 20th year of uninterrupted funding. Over the past two decades, the CCSG has provided indispensable support to the research programs of RPCI. The present CCSG application reflects the significant evolution and progress of RPCIs research programs with the inclusion of 6 mature programs, 2 developing programs and 12 shared resources, seven of which are new or significantly expanded resources carried over from the merger of the Institute Core Grant with the Grace Cancer Drug Center Core Grant. Since the last CCSG renewal, there have been numerous changes in the RPCI research programs including recruitment of new senior faculty, scientific and clinical departments have been reorganized, major capital investments and the commitment of New York State to design and build a new research laboratory, vivarium, nursing tower, ambulatory clinic and diagnostic and treatment facility, all in addition to major renovations to existing research facilities. The CCSG plays a central role in the planning and evaluation, support and administration of Roswell's basic and clinical research programs. With the renewal of this CCSG, combined with the commitment of New York State to support the cancer mission of Roswell Park and its highly dedicated research faculty, Roswell Park will be poised to enter the next century as one of the nations leading cancer centers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440
Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652
Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940
Merzianu, Mihai; Groman, Adrienne; Hutson, Alan et al. (2018) Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study. Am J Clin Pathol 150:393-405
Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Muramatsu, Masashi; Akakura, Shin; Gao, Lingqiu et al. (2018) SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget 9:33515-33527
Kumar, Sandeep; Inigo, Joseph R; Kumar, Rahul et al. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82-93
Liu, Chunhong; Yu, Tao; Xing, Zhuo et al. (2018) Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. Oncotarget 9:4773-4786
Cimato, Thomas R; Conway, Alexis; Nichols, Julianne et al. (2018) CD133 expression in circulating hematopoietic progenitor cells. Cytometry B Clin Cytom :

Showing the most recent 10 out of 1555 publications